home / stock / srpt / srpt quote
Last: | $125 |
---|---|
Change Percent: | -1.87% |
Open: | $122.22 |
Close: | $125 |
High: | $125.84 |
Low: | $122.22 |
Volume: | 1,366,464 |
Last Trade Date Time: | 06/13/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$125 | $122.22 | $125 | $125.84 | $122.22 | 1,366,464 | 06-13-2024 |
$119.98 | $122.93 | $119.98 | $123.53 | $118.7 | 701,721 | 06-12-2024 |
$121.38 | $121.48 | $121.38 | $122.56 | $119.62 | 682,470 | 06-11-2024 |
$122.59 | $123.13 | $122.59 | $124.41 | $121.68 | 1,636,235 | 06-10-2024 |
$123.32 | $117.53 | $123.32 | $124.6 | $116.52 | 1,485,701 | 06-07-2024 |
$117.44 | $119.2 | $117.44 | $119.44 | $116.93 | 1,283,601 | 06-06-2024 |
$119.79 | $119.75 | $119.79 | $122.53 | $116.5 | 1,795,025 | 06-05-2024 |
$119.72 | $123.79 | $119.72 | $124.22 | $118.87 | 1,125,314 | 06-04-2024 |
$124.23 | $128.53 | $124.23 | $128.53 | $122.64 | 1,809,623 | 06-03-2024 |
$129.86 | $125.48 | $129.86 | $130.81 | $125.4 | 16,976,044 | 05-31-2024 |
$124.45 | $122.95 | $124.45 | $125.725 | $120.23 | 4,369,473 | 05-30-2024 |
$116.25 | $113.37 | $116.25 | $117.08 | $112.395 | 1,942,588 | 05-29-2024 |
$113.33 | $119.02 | $113.33 | $120 | $109.91 | 2,977,049 | 05-28-2024 |
$123.46 | $128 | $123.46 | $129 | $123.31 | 1,033,844 | 05-27-2024 |
$123.46 | $128 | $123.46 | $129 | $123.31 | 1,033,844 | 05-24-2024 |
$127.13 | $128.12 | $127.13 | $129.84 | $125.5 | 847,705 | 05-23-2024 |
$128.3 | $128.93 | $128.3 | $130.94 | $127.66 | 723,257 | 05-22-2024 |
$129.12 | $130.11 | $129.12 | $131.025 | $127.68 | 748,484 | 05-21-2024 |
$130.83 | $132.15 | $130.83 | $132.15 | $128.75 | 779,919 | 05-20-2024 |
$131.38 | $132.88 | $131.38 | $133.12 | $129.5 | 849,008 | 05-17-2024 |
News, Short Squeeze, Breakout and More Instantly...
Sarepta Therapeutics Inc. Company Name:
SRPT Stock Symbol:
NASDAQ Market:
Sarepta Therapeutics Inc. Website:
Pfizer (NYSE: PFE) announced that a phase III study on its mini-dystrophin gene therapy fordadistrogene movaparvovec for treating Duchenne muscular...
2024-06-13 15:15:01 ET Citigroup analyst issues BUY recommendation for SRPT on June 13, 2024 01:18PM ET. The previous analyst recommendation was Buy. SRPT was trading at $123.865 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ana...
2024-06-13 11:00:06 ET Brian Skorney from Robert W. Baird issued a price target of $170.00 for SRPT on 2024-06-13 10:14:00. The adjusted price target was set to $170.00. At the time of the announcement, SRPT was trading at $124. The overall price target consensus is at $...